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Tibolone, a synthetic steroid, is effective in the treatment of postmenopausal symptoms. The 
cardiovascular safety profile of tibolone has been questioned, because it reduces the levels of 
cardioprotective high-density lipoprotein (HDL) cholesterol. Soy-derived isoflavones may offer 
health benefits, particularly as regards circulating lipids and also other cardiovascular risk factors. 
The soy-isoflavone metabolite equol is thought to be the key as regards soy-related beneficial 
effects. We studied the effects of soy supplementation on various cardiovascular disease (CVD) 
risk factors in postmenopausal monkeys and postmenopausal women using tibolone. Additionally, 
the impact of equol production capability was studied. 
 A total of 18 cynomolgus monkeys were assigned to receive casein/lactalbumin (C/L) 
(placebo), tibolone, soy (a woman’s equivalent dose of 138 mg of isoflavones per day), or soy 
with tibolone in a random order in such a way that all animals received all four diets. Each 
treatment phase lasted for 14 weeks, and there was a 4-week washout diet (C/L) before starting the 
next treatment regimen. Postmenopausal women undergoing long-term tibolone use (N=110) were 
screened by means of a one-week soy challenge to find 20 women with equol production 
capability (4-fold elevation from baseline equol level) and 20 control women. Both groups were 
treated in a randomized placebo-controlled cross-over trial with a soy powder (52 g of soy protein 
containing 112 mg of isoflavones per day) or placebo for 8 weeks. Before and after the treatments 
lipids and lipoproteins were assessed in both monkeys and women. In addition, blood pressure, 
arterial stiffness, endothelial function, sex steroids, sex hormone-binding globulin (SHBG), and 
vascular inflammation markers were assessed before and after soy and placebo supplementation.  
A 14% increase in plasma low-density lipoprotein (LDL) + very low-density 
lipoprotein (VLDL) cholesterol was observed in tibolone-treated monkeys versus the placebo 
group (Tibolone vs. C/L p=0.004). Soy treatment resulted in a 18% decrease in plasma 
LDL+VLDL cholesterol (Soy vs. C/L p=0.0002), and concomitant supplementation with tibolone 
did not negate the LDL+VLDL cholesterol-lowering effect of soy (Soy+Tibolone vs. Soy p=0.35). 
A 30% increase in HDL cholesterol (Soy vs. C/L p<0.0001) was observed in monkeys fed with 
soy, whereas HDL cholesterol levels were reduced (~48%) after tibolone (Tibolone vs. C/L 
p<0.0001). Interestingly, Soy+Tibolone diet conserved HDL cholesterol levels (Soy+Tibolone vs. 
C/L p=0.09). Monkeys treated with tibolone alone showed an increase in total cholesterol 
(TC):HDL cholesterol ratio of 118% compared with placebo (Tibolone vs. C/L p<0.0001). Those 
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treated with Soy or Soy+Tibolone showed reductions of 34% (Soy vs. C/L p=0.03) and 2.4% 
(Soy+Tibolone vs. C/L p=0.84, Soy+Tibolone vs. Soy p=0.05) in the TC:HDL cholesterol ratio. 
  In postmenopausal women using tibolone, reductions in the levels of total cholesterol 
(p=0.06) and LDL cholesterol (p=0.006) were seen after soy supplementation compared with 
placebo. In contrast to the monkeys, in women soy supplementation had no effect on HDL. In 
addition, blood pressure, arterial stiffness and endothelial function were unaffected by soy 
supplementation in women using tibolone. Circulating levels of estrone decreased after soy 
supplementation, but only in equol producers (12.5% decrease; p=0.04), and the levels of 
testosterone decreased by 15.5% (p=0.02) in the entire study population. No changes were seen in 
the circulating concentrations of androstenedione, dehydroepiandrosterone sulfate (DHEAS), or 
SHBG. Circulating concentrations of vascular cell adhesion molecule-1 (VCAM-1) increased by 
9.2% (p=0.06), and platelet-selectin (P-selectin) decreased by 10.3% (p=0.002) after soy 
treatment, whereas C-reactive protein (CRP) and intercellular adhesion molecule-1 (ICAM-1) 
remained unchanged. At baseline and unrelated to soy treatment, equol producers had lower 
systolic (129.9±2.6 [SEM] vs. 138.5±3.1 mmHg; p=0.02), diastolic (72.2±1.5 vs. 76.6±1.3 mmHg; 
p=0.01) and mean arterial (93.5±1.7 vs. 99.9±1.8 mmHg; p=0.007) pressures compared with non-
producers. Similarly, baseline arterial stiffness was less (25.9±1.1% vs. 29.6±0.9%; p=0.01), and 
endothelial function better (72.3±5.3% vs. 55.2±3.8%; p=0.009) in equol producers than non-
producers. 
 To conclude, soy supplementation reversed the tibolone-induced fall in HDL 
cholesterol levels in postmenopausal monkeys. However, this effect of soy was not seen in 
postmenopausal women taking tibolone. In these women soy supplementation also failed to 
modify blood pressure, arterial stiffness and endothelial function, but determined by these CVD 
risk factors, equol production capability itself was associated with beneficial cardiovascular 
changes. Our findings imply that there are cardiovascular benefits associated with equol-producing 













A well established fact is that the risk of cardiovascular diseases (CVDs) increases soon after the 
onset of menopause (Rosano et al. 2007), particularly in women who have entered menopause 
earlier than normal (Maxwell 1998, Lobo 2007). The mechanisms behind this phenomenon are not 
fully understood, but the decline in the concentrations of estrogens could be a key factor (Rexrode 
et al. 2003, Rosano et al. 2007). This is further supported by data showing that the use of 
postmenopausal hormone therapy (HT), if initiated early in menopause, may protect against the 
risk of CVD (Manson et al. 2007, Mendelsohn and Karas 2007), although this evidence has been 
vigorously disputed in recent years (Barrett-Connor et al. 2005). However, HT also has 
unavoidable risks and side-effects, the most feared being the increased risk of breast cancer 
(Foidart et al. 2007). In addition, HT is associated with an increased risk of venous 
thromboembolic events (Mendelsohn and Karas 2005). Alternatives to traditional HT are therefore 
needed. As CVD continues to be the leading cause of morbidity and mortality among 
postmenopausal women, the cardiovascular effects of optional menopause treatments need to be 
evaluated.  
Tibolone, a synthetic steroid, is effective in the treatment of climacteric symptoms 
and in prevention of osteoporosis (Kenemans and Speroff 2005). Its use, however, is shadowed by 
a fall in the circulating concentrations of cardioprotective high-density lipoprotein (HDL) 
cholesterol (Mikkola and Clarkson 2002, Notelowitz 2007), and by increased progression in 
carotid artery intima-media thickness (CIMT) (Bots et al. 2006). Therefore, the cardiovascular 
safety of tibolone has been questioned.  
Postmenopausal women often use various botanical supplements (Albertazzi and 
Purdie 2002), concomitantly with traditional HT or tibolone (Mahady et al. 2003, Low Dog 2005). 
Among alternative treatments are phytoestrogens, plant-derived compounds possessing estrogenic 
activity (Murkies et al. 1998) and with features of Selective Estrogen Receptor Modulators 
(SERMs) (Wuttke et al. 2003). Isoflavones, which represent the main class of the most common 
phytoestrogens, are abundantly present in soybeans (Murkies et al. 1998, Valachovicova et al. 
2004). Soy-derived isoflavones have been considered as potential alternatives to traditional HT, 
although they have little or no effect in the relief of climacteric symptoms (Nikander et al. 2003a, 
Tempfer et al. 2007). Compared with Western countries, the consumption of soy is high in Asia, 
where the incidences of CVD and breast cancer are low. This may partly be explained by 
differences in lifestyle and diet (Tikkanen and Adlercreutz 2000, Valachovicova et al. 2004), but 
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the use of soy may be an additional factor. In this regard, equol, an isoflavone metabolite, may be 
in a key position (Setchell et al. 2002, Setchell et al. 2005). It is produced by intestinal bacterial 
flora from soy-derived daidzein. This characteristic, which is present only in approximately one 
third of humans, may also affect steroid metabolism (Duncan et al. 2000, Frankenfeld et al. 
2004a). 
Since tibolone and soy are commonly taken together, it is important to study the 
extent to which soy supplementation modifies the vascular effects of tibolone. Clinical prospective 
studies would take years, and therefore, before initiating such studies it is wise to assess the effects 
of soy in women using tibolone with the aid of established vascular surrogate markers. This was 































In Finland, approximately 40 000-50 000 women enter menopause annually, typically at the age of 
50-52 years. As the mean life expectancy for a Finnish woman is almost 81 years, women will live 
approximately 30 years in a postmenopausal state. Menopause may also result from oophorectomy 
or chemotherapy ending the function of the ovaries. At menopause, ovarian secretion of estrone 
and 17β-estradiol drastically decreases, but the ovaries continue to produce androgens, such as 
testosterone, androstenedione and dehydroepiandrosterone (DHEA) (Figure 1). In addition, the 
adrenal cortex secretes androstenedione, DHEA and its sulfated form (DHEAS). The conversion 
of these steroids to more active hormones, including estrone, 17β-estradiol and testosterone, takes 
place primarily in the peripheral adipose tissue, but also in bone, vascular endothelium and brain 
(Simpson 2002). Indeed, postmenopausal women gain estrogens primarily from androgens through 
peripheral aromatization, and the most abundant estrogen in postmenopausal women is estrone 
(Speroff and Fritz 2005).  
Two nuclear estrogen receptors (ERs), alpha and beta (ERα and ERβ), have been 
discovered. In addition, ERs acting on the cell membrane have been found (Fu and Simoncini 
2008, Kampa et al. 2008). Estrogen receptors are present in the reproductive tract, bone, brain, and 
breast, and also in adipose tissue, liver, intestine, kidney, lungs and cardiovascular tissue (Gruber 
et al. 2002, Mendelsohn 2002, Mendelsohn and Karas 2005). The ratios of ERα and ERβ in 
different tissues may change after menopause (Mendelsohn and Karas 2005). The decline in 
circulating estrogens appears to be accompanied by health risks in postmenopausal women, 
particularly in women who have entered menopause earlier than usual (Maxwell 1998, Stearns et 
al. 2002, Gallagher 2007, Lobo 2007). In the central nervous system estrogen deficiency may 
result in vasomotor symptoms, such as hot flushes, which are so typical that they can be regarded 
as diagnostic as regards the onset of menopause (Nelson 2008).  
In addition to hot flushes, climacteric symptoms may comprise night sweats, 
palpitation, mood swings, disturbed night sleep, vaginal dryness and decreased libido (Stearns et 
al. 2002, Freeman and Sherif 2007). These symptoms, which are present in approximately 80% of 
postmenopausal women, are disturbingly severe in 20% (Stearns et al. 2002). Hot flushes persist 
for over 5 years in 30% and for over 15 years in 20% of postmenopausal women (Stearns et al. 
2002). After menopause the risk of osteoporosis increases as a result of activated bone resorption 
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and reduced bone formation, both of which are regulated by estrogen (Andersen 2007). 
Furthermore, estrogen deficiency is associated with an increased risk of CVD (Mendelsohn and 













Figure 1.  
Principles of estrogen metabolism in postmenopausal women; 3β-HSD: 3-beta-hydroxysteroid 
dehydrogenase; 17β-HSD: 17-beta-hydroxysteroid dehydrogenase; 5α-reductase: 5-alpha-reductase.                         
                     
                   
 Ovaries, adrenal cortex           Dehydroepiandrosterone (DHEA)  →  DHEA sulfate (DHEAS) 
 
                                             3β-HSD    ↓                                            
                                                                                                                  17β-HSD                      5α-reductase 
 Ovaries, adrenal cortex           Androstenedione  ↔ Testosterone  →  Dihydrotestosterone (DHT) 
 
                                             aromatase   ↓                          ↓  aromatase 
        17β-HSD      
 Peripheral aromatization         Estrone            ↔          17β-estradiol      







Approximately 10 000 women in Finland (www.stat.fi) and 8.6 million women worldwide (The 
World Health Report 2004, World Health Organization) die of CVD every year. In premenopausal 
women the incidence of CVD is lower than in men of the same age group, but it rises markedly at 
and after the onset of menopause (Kannel et al. 1976, Maxwell 1998, Collins et al. 2007). 
Cardiovascular disease is manifest in women approximately a decade later than in men (Collins et 
al. 2007). Indeed, among postmenopausal women CVD is the leading cause of morbidity and 
mortality (Mendelsohn and Karas 2005).  
There are abundant data on the gender differences that exist in the symptoms, 
progression, prognosis and management of CVDs (Collins et al. 2007). During the past few years, 
the incidence of coronary heart disease (CHD) in women has been rising perhaps as a result of 
neglected prevention and management strategies (Hanratty et al. 2000, Lundberg et al. 2002, 
Herrington and Klein 2003, Collins et al. 2007). Moreover, in clinical practice, CHD in a woman 
is often diagnosed later than in men, and this leads to retarded initiation of treatment. 
Postmenopausal women with CVD risk factors, such as diabetes, insulin resistance, 
hyperlipidemia, hypertension, and overweight – all of which are components of the metabolic 
syndrome and affected by hormonal changes at the menopausal transition – indicate a higher risk 
of CVD-associated mortality in women than in men of the same age (Hu 2003, Collins et al. 
2007). The exact mechanisms behind this phenomenon are not fully understood, but several 




As mentioned earlier, menopause is associated with an increased risk of CVD (Mendelsohn and 
Karas 2005). One explanation may be hypoestrogenism, because estrogen has several favorable 
effects on the cardiovascular system (Table 1). These include, for example, the ability to reduce 
the levels of low-density lipoprotein (LDL) cholesterol and increase those of HDL cholesterol, and 
to promote vasodilation by altering the production of vasoactive molecules (Mendelsohn and 
Karas 1999, Mendelsohn 2002). Indeed, in a recent study estrogen was associated with reduced 





Polycystic ovary syndrome and hyperandrogenism 
 
High levels of androgens may jeopardize cardiovascular health through adverse effects on lipids, 
blood pressure and glucose metabolism (Rexrode et al. 2003). Hyperinsulinemia may lead to 
hyperandrogenism, as insulin stimulates testosterone production in the ovaries. In addition, 
hyperinsulinemia inhibits the synthesis of sex hormone-binding globulin (SHBG), which at low 
levels is associated with an increased risk of atherosclerosis (Reinecke et al. 2002, Salley et al. 
2007, Liepa et al. 2008). An example of hyperandrogenism is in cases of polycystic ovary 
syndrome, which is associated with an increased risk of CVD (Martikainen et al. 1998, Liepa et al. 
2008). The effects of androgens and estrogens may differ in women and men; in middle-aged 
women with CVD levels of androgens have been reported to be lower than in their compared 
controls (Khatibi et al. 2007). In contrast in men, there have also been implications of a beneficial 
effect of endogenous testosterone on serum lipids (Mäkinen et al. 2008). Overall, the role of sex 























Possible mechanisms by which estrogen deficiency may increase the risk of cardiovascular disease 
(LDL: low-density lipoprotein; HDL: high-density lipoprotein). 
Target organ/system Effect Reference (reviews or meta-
analyses) 
Blood pressure Increase in blood pressure 
 
Mendelsohn and Karas 2005 
(review) 
Body fat Android pattern in body fat, 
increase in visceral fat 
Rosano et al. 2007 (review) 
Glucose metabolism  Glucose intolerance 
 
Rosano et al. 2007 (review) 
Lipid metabolism Lipid profile becomes more 
atherogenic; increase in total 
cholesterol, LDL cholesterol, 
triglycerides and 
lipoprotein(a), and decrease in 
HDL cholesterol  
Tikkanen 1996a (review), 
Godsland 2001 (meta-
analysis), Rosano et al. 2007 
(review) 
 
Vascular function Endothelial dysfunction, 
reduced vasodilation 






Elevated levels of serum cholesterol predispose individuals to atherosclerosis, even in the absence 
of other risk factors (Schoen 2005). In the circulation, the major apolipoprotein-B-containing 
lipoproteins transporting cholesterol are LDL, very low-density lipoprotein (VLDL), HDL and 
lipoprotein(a) (Tikkanen 1996b, Stangl et al. 2002). Before menopause, the levels of total 
cholesterol and LDL cholesterol are lower and the level of HDL cholesterol is higher in women 
than in men, whereas after menopause the opposite situation develops. This may contribute to the 
rise in the risk of CVDs in postmenopausal women (Tikkanen 1996a).  
Low-density lipoprotein cholesterol is essential in the delivery of cholesterol to 
peripheral tissues (Schoen 2005). In the early stages of atherosclerosis LDL cholesterol is oxidized 
by free radicals. The oxidized LDL particles are scavenged by macrophages or smooth muscle 
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cells and become aggregated in the arterial wall (Moore and Freeman 2006); accumulation of 
lipids leads to the formation of foam cells and further to fatty streaks, which may also contain 
lymphocytes and platelets (Moore and Freeman 2006, Gossi et al. 2007, Kolodgie et al. 2007). 
Fatty streaks develop to atherosclerotic plaques which may eventually rupture and lead to 
occlusion of the artery (Moore and Freeman 2006, Kolodgie et al. 2007). 
At low level HDL cholesterol is a major risk factor of CVDs, particularly in women 
(Rosano et al. 2007), whereas at high level HDL cholesterol confers cardioprotection (Tikkanen 
and Nikkilä 1987, Collins et al. 2007). The impact of decreased levels of HDL cholesterol is 
important, because HDL particles have a role in cholesterol transport from cells to the liver for 
excretion (Schoen 2005). This process called cholesterol efflux is an independent predictor of 
coronary artery atherosclerosis (Mikkola et al. 2003). 
In addition to lipoproteins, triglycerides play a significant role in lipid metabolism 
(Schoen 2005). Triglycerides are derived from free fatty acids from the adipose tissue or from 
ingested foods. In the liver, fatty acids are esterified to triglycerides, which associate with 
apoproteins. Increased levels of triglycerides have been recognized as an independent risk factor of 
CVD, again particularly in women (Stangl et al. 2002, Collins et al. 2007). Simultaneous 
elevations in LDL cholesterol and reduction in HDL cholesterol augment the atherogenic risk of 
hypertriglyceridemia.  
On the basis of the results of a large meta-analysis, the ratio of total cholesterol/HDL 
cholesterol is the strongest predictor of ischemic heart disease (Prospective Studies Collaboration 
2007). Lowering total cholesterol by 1 mmol/l reduces the risk of dying from ischemic heart 
disease in both sexes, and in women it is most conspicuous in middle-aged subjects 
(approximately 30-50% lower mortality). Thus, lowering total cholesterol is beneficial, but 
improvement of LDL, VLDL and HDL cholesterol and triglycerides status is at least equally 
important. Furthermore, the impact of non-HDL, apoB and particularly LDL particle concentration 
is attracting more attention as regards assessment of CHD risk (Davidson 2008, Hsia et al. 2008). 





Hypertension is the leading CVD risk factor (Appel et al. 2006, Kshirsagar et al. 2006). The risk 
of CVD rises progressively through the range of blood pressure beginning with normotensive 
values (Miller and Jehn 2004, Appel et al. 2006, Messerli et al. 2007). Many apparently healthy 
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menopausal women have slightly elevated blood pressure (Appel et al. 2006). According to the 
Framingham Study, 55-year-old postmenopausal women have a 90% lifetime probability of 
developing hypertension (Vasan et al. 2002). Individuals with blood pressure ranging from 130-
139/85-89 mmHg have a 2-fold risk of CVD compared with normotensive subjects. Moreover, 
each 20/10 mmHg increase in systolic/diastolic blood pressure doubles the risk of developing 
CVD (Miller and Jehn 2004). The present guidelines are that blood pressure is optimal if 
<120/<80 mmHg, normal if 120-129/80-84 mmHg, high normal if 130-139/85-89 mmHg, and 
hypertensive if >140-159/90-99 mmHg (Consensus Statement of the Finnish Medical Society of 
Duodecim and the Finnish Association of Hypertension 2006, ESH-ESC 2007 guidelines for the 
management of arterial hypertension). These guidelines are infrequently met in clinical practice in 




Development of atherosclerosis can also be considered as an inflammatory process, which is 
initiated with the adherence of leukocytes to damaged endothelium (Lind 2003) (Figure 2). 
Arterial endothelial cells express vascular cell adhesion molecule-1 (VCAM-1), which binds 
monocytes and T-lymphocytes (Schoen 2005). Monocytes adhere to the endothelium, migrate to 
the intima and are transformed into macrophages, which scavenge lipoproteins and become foam 
cells. This process is initially protective as potentially harmful lipid particles are removed, but 
progressive accumulation of lipid-laden macrophages in the arterial wall promotes atherosclerosis. 
Leukocytes release inflammatory cytokines, which may stimulate the actions of macrophages, 
vascular endothelial cells and smooth muscle cells. Smooth muscle cells migrate from the arterial 
media to the intima, proliferate and convert fatty streaks into fibrofatty atheromas and 
atherosclerotic plaques (Schoen 2005). Vascular inflammation also weakens the fibrous cap of the 
atherosclerotic plaque, leading to its rupture (Lind 2003) (Figure 2).  
A number of inflammatory biomarkers have been used as risk indicators of CVD 
(Blankenberg et al. 2003, Lind 2003). These include C-reactive protein (CRP), various adhesion 
molecules, selectins, fibrinogen, leukocytes, cytokines and leukocyte cell surface antigens. Among 
these the most established are CRP, VCAM-1, intercellular adhesion molecule-1 (ICAM-1), 
platelet-selectin (P-selectin) and endothelial-selectin (E-selectin) (Blankenberg et al. 2003, Lind 





Sources and functions of C-reactive protein (CRP), vascular cell adhesion molecule-1 (VCAM-1), 
intercellular adhesion molecule-1 (ICAM-1), endothelial-selectin (E-selectin) and platelet-selectin 
(P-selectin), which are often used as vascular inflammation markers. 
Marker Source Function Reference 
(reviews) 
CRP Liver Complement activation, 
counteraction of infections 
Lind 2003 
VCAM-1 Endothelial cells, 
smooth muscle cells, 
tissue macrophages 
Signal induction in endothelial cells 
causing leukocyte migration 
Blankenberg et 
al. 2003, Brevetti 
et al. 2008 
ICAM-1 Endothelial cells, 
smooth muscle cells, 
tissue macrophages 
Adhesion of leukocytes to the 
endothelium; leukocyte extravasation 
Blankenberg et 
al. 2003, Brevetti 




smooth muscle cells, 
tissue macrophages 
Early leukocyte recruitment at the 
endothelium 
Blankenberg et 
al. 2003, Lind 
2003 
P-selectin Platelets, endothelial 
cells 






Arterial stiffness and endothelial dysfunction 
 
Vascular function can be assessed from the central aortic pulse wave. It is formed from the 
combination of the forward-moving pressure wave generated by the left ventricle in systole and 
waves reflected back to the aorta from points of greater impedance along the arterial tree, such as 
bifurcations and arterioles (Segers et al. 2001). Arteries lose their elasticity with advancing age 
and thus arterial stiffness also increases in an age-related pattern (Mackenzie et al. 2002, Rönnback 
et al. 2004). Hence, young arteries differ from old ones as regards the shape of the arterial pressure 
waveform and this serves as a measure of arterial stiffness (Segers et al. 2001). In young persons 
the reflected waves reach the ascending aorta in late systole. In the elderly and perhaps 
hypertensive subjects the magnitude and speed of the waves are increased and add to the forward 
wave in early systole, thus boosting the systolic pressure (Segers et al. 2001). Consequently, pulse 
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pressure (the difference between systolic and diastolic blood pressure) increases with advancing 
age and it indicates arterial stiffness (Mackenzie et al. 2002, Rönnback et al. 2004). 
The outer layer of arteries, adventitia, is formed mainly of collagen fibers and 
fibroblasts. The middle layer, media, contains smooth muscle cells. The inner layer, intima, is 
formed of an elastic part (interna elastica) and endothelial cells. This endothelium lines the surface 
of the intima closest to the lumen of the artery (Schoen 2005) (Figure 2). Several biologically 
active mediators regulating vascular tone (such as nitric oxide [NO], prostacyclin, endothelin, 
angiotensin, and thromboxane), coagulation and fibrinolysis, as well as growth factors and 
immunological mediators are released by the endothelium (Brevetti et al. 2008).  
Intact endothelial cells are essential for vascular health, whereas endothelial 
dysfunction predisposes individuals to vascular disorders (Schoen 2005). The specific cause of 
endothelial dysfunction is not known, but homocysteine, cytokines, viruses and other infectious 
agents as well as circulating derivatives of cigarette smoke, are potentially involved. The most 
important determinants of endothelial alterations are, however, thought to be hemodynamic 
disturbances and adverse effects of hypercholesterolemia, either together or alone (Schoen 2005). 
Endothelial function can be assessed from plasma levels of endothelial cell-generated molecules, 
such as endothelin-1, intercellular and vascular adhesion molecules and nitrite/nitrate (Brevetti et 
al. 2008). Vascular reactivity may be evaluated by studying flow-mediated dilation, arterial 
stiffness, or pulse-wave velocity. The ability of the endothelium to release NO is often used as a 
measure of endothelial function (Cockcroft 2005). Endothelial dysfunction is also associated with 
other risk factors of CVD, for example, hypercholesterolemia, hypertension, age, smoking and 
diabetes, and in practice it is difficult to delineate which change is primary and which one is 
secondary (Sarabi et al. 2001). Arterial stiffness and endothelial dysfunction are early signs of 
arteriosclerosis and can be detected before clinically evident vascular disease (Mackenzie et al. 












Structure of a normal artery and the formation of atherosclerotic plaque in the arterial wall. 
Reprinted with permission from Macmillan Publishers Ltd: Nat Rev Genet 2006; 7: 163-173 
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Estrogen is the most effective treatment for vasomotor symptoms. In women with an intact uterus 
estrogen is combined with progestagen (estrogen-progestagen therapy; EPT) to avoid endometrial 
hyperplasia and cancer. Estrogen-only therapy (ET) is used in hysterectomized women. Estrogen 
is most commonly administered orally or transdermally. Traditional HT effectively relieves 
climacteric symptoms, prevents osteoporosis, and improves the quality of life (Nelson 2008). The 
various ET and EPT regimens vary in content and dose, and in order to maximize safety, current 
recommendations are that the lowest dose of HT should be prescribed for the shortest duration 
necessary to relieve climacteric symptoms (Nelson 2008, Utian et al. 2008).   
There are several mechanisms by which estrogen may improve vascular health. These 
include, for example, changes in lipid/lipoprotein metabolism, arterial relaxation by endothelium-
dependent and -independent mechanisms, stimulation of endothelial cell proliferation and 
migration, inhibition of smooth muscle cell growth, contribution to the repair of injured blood 
vessels and inhibition of intimal thickening (Mikkola et al. 1995, Ylikorkala et al. 1995, 
Mendelsohn and Karas 1999). Data from several studies imply that the use of HT reduces the risk 
of CVD in previously healthy postmenopausal women by 35-50% (Mendelsohn and Karas 1999, 
Grady et al. 2002, Mikkola and Ylikorkala 2005).  
In the past few years, traditional HT has been the subject of major criticism because 
of reports on the results of randomized clinical trials in which the risks of HT have appeared to 
outweigh the benefits (Writing Group for the Women’s Health Initiative Investigators 2002, 
Herrington and Klein 2003, Million Women Study Collaborators 2003). The adverse outcomes 
were mainly increases in cardiovascular events (CHD, stroke, venous thromboembolic disease) 
and breast cancer cases, although there were differences and limitations in the study designs. 
Overall, the previous assumption that HT would offer protection against CVD regardless of time 
elapsed since the onset of menopause has been rejected (some time ago) (Ylikorkala 2000, Mikkola 
and Ylikorkala 2005, Manson et al. 2007, Clarkson 2008). Some leading studies and trials are 
reviewed below.   
Of the various observational studies, The Nurses’ Health Study (NHS) is the most 
comprehensive one. It was started in 1976 when 70533 postmenopausal nurses were recruited and 
followed-up for 20 years. In this large cohort, when adjusted for age and common CVD risk 
factors, current use of HT was associated with a 39% reduced risk of a major coronary event 
(Grodstein et al. 2000). In postmenopausal nurses with known previous myocardial infarction or 
atherosclerosis, the recurrence rate was increased by 25% with short-term HT, whereas it was 
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decreased by 62% with long-term use of HT compared with never-users of HT (Grodstein et al. 
2001, Speroff 2001). 
The Heart and Estrogen/progestin Replacement Study (HERS) involved a total of 
2763 postmenopausal women with a history of CHD who were enrolled to receive conjugated 
equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) or placebo for 4.1 years. This 
was the first randomized and placebo-controlled trial in which the use of HT in regard to CHD was 
assessed. The use of CEE+MPA did not reduce the risk of CHD mortality or other CVD outcome 
compared with placebo (95% CI 0.81-1.22) and therefore the use of EPT was not recommended 
for secondary prevention of CHD (Hulley et al. 1998). It was also noted that the risk of recurrent 
coronary events was highest in the first year (52% increase), after which the differences between 
treated and untreated women began to settle and during years 3-5 CEE+MPA was associated with 
a lower risk (33-13%) of coronary events (Hulley et al. 1998), but after 6.8 years the overall risk of 
CVD was not reduced (Grady et al. 2002).  
The randomized Women’s Health Initiative (WHI) study involving 27347 
postmenopausal women treated with CEE+MPA, unopposed CEE in hysterectomized women, or 
placebo, was aimed at confirming the observational findings that HT is beneficial in primary 
prevention of CHD. However, the results of the WHI study failed to support this hypothesis, as 
CEE+MPA was associated with a 22% increased risk of total CVDs and a 29% increased risk of 
CHD (Writing Group for the Women’s Health Initiative Investigators 2002). In the WHI sub-
study, ET was associated with 45% less coronary artery calcification among 50- to 59-year-old 
women compared with placebo, although it remained unclear whether this phenomenon would 
persist if ET was initiated at a younger age (Manson et al. 2007). Overall, HT was not 
recommended for the primary prevention of CVD (Manson et al. 2003, Manson et al. 2007). 
Hormone therapy may, however, be beneficial as regards the risk of CVD if it is initiated soon 
after the onset of menopause and not several years later (Dubey et al. 2005, Manson et al. 2007, 
Mendelsohn and Karas 2007, Rossouw et al. 2007).  
The most common adverse effect associated with HT is the increased risk of breast 
cancer (Writing Group for the Women’s Health Initiative Investigators 2002, Foidart et al. 2007), 
which appears to depend on the duration of HT use, different formulations of ET/EPT, and route 
of administration (oral vs. transdermal) (Collins 2006, Lyytinen et al. 2006, Foidart et al. 2007, 
Opatrny et al. 2008). Similarly, different lipid and metabolic effects may also be expected 
depending on the type of HT and particularly on whether it is taken orally or transdermally 
(Strandberg et al. 2003). In addition, some women experience side-effects of HT, such as breast 
tenderness, uterine bleeding, nausea, headache and weight change (Vihtamäki et al. 1999, Nelson 
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2008). Fortunately, postmenopausal women and their physicians have the possibility to choose 
from the numerous HT regimens available. Nevertheless, HT can hardly be considered as an ideal 
treatment. Several guidelines indicate that the use of HT is justified for the relief of climacteric 
symptoms in appropriate populations. Importantly, an individual risk profile should be evaluated 
for each woman considering initiation of ET/EPT (Consensus Statement of the Finnish Medical 
Society of Duodecim and the Academy of Finland 2004, Grady and Barrett-Connor 2007, Utian et 





Tibolone, (7α,17α)-17-hydroxy-7α-methyl-19-nor-17α-pregn-5(10)-en-20-yn-3-one is a synthetic 
steroid used as an alternative treatment for climacteric symptoms and the prevention of 
osteoporosis (Vos et al. 2002). Tibolone is given orally at a daily dose of 2.5 mg. It was introduced 
in 1988 and at present it represents the most popular menopausal treatment in Europe. Tibolone is 
currently not available in the United States. In Finland, approximately 15 000 women use tibolone 
(The Social Insurance Institute of Finland).  
  
Metabolism and mode of action 
 
The metabolism of tibolone occurs mainly in the intestine and the liver (Kloosterboer 2001). It is 
metabolized to three biologically active compounds, two of them being the estrogenic metabolites 
3α-hydroxy (OH)-tibolone and 3β-hydroxy (OH)-tibolone, both of which bind to ERs (Figure 3). 
Because it has estrogenic metabolites, tibolone relieves hot flushes and reduces the risk of 
osteoporosis and vaginal atrophy (Kloosterboer 2001, Notelovitz 2007). The third metabolite is Δ4-
isomer which binds to androgen and progesterone receptors (Kloosterboer 2001, Campisi and 
Marengo 2007, Notelovitz 2007) (Figure 3). Due to a locally formed progestin in the endometrium, 
the use of tibolone does not result in withdrawal bleeding. In addition, tibolone has a positive 
effect on mood and sexual well-being. This is likely to be the result of the androgenic effects of 
the Δ4-isomer and/or the reduction in the levels of SHBG and subsequent increase in the levels of 
free testosterone (Kloosterboer 2001). Tibolone has been associated with reduced breast 
mammographic density in comparison with a conventional form of HT (Notelovitz 2007). 
However, when a total of 3148 women with a history of breast cancer were treated with tibolone 
(2.5 mg) or placebo for four years, the risk of recurrence/new breast cancer was 48% higher in 
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women scheduled to tibolone (Kenemans 2008, Ylikorkala, personal communication). In contrast, 
a lower dose of tibolone (1.25 mg) has been associated with a 68% decreased risk of primary 


































Structure of tibolone and its metabolites. The main target effects are also mentioned. 
OH: hydroxy; Δ4: delta-four. For comparison, see Figure 4 for the structure of 17β-estradiol. 
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Many studies have been concerned with assessment of the effects of tibolone on several 
established CVD risk factors (Table 3). Tibolone does not affect blood pressure (Lloyd et al. 2000, 
Cagnacci et al. 2004) and it may reduce arterial stiffness and improve endothelial function (Bruce 
et al. 2005, Castelo-Branco et al. 2005, Somunkiran et al. 2006). Furthermore, tibolone has been 
shown to increase plasma levels of NO in postmenopausal women, implying a possible 
cardioprotective effect (Cicinelli et al. 2002). Moreover, it reduces the circulating levels of cell 
adhesion molecules, such as VCAM-1, ICAM-1 (Egarter et al. 2003, Cicinelli et al. 2006) and 
selectins (Cicinelli et al. 2006, Sator et al. 2006), or leaves them unchanged (Vitale et al. 2005). 
Yet, tibolone may increase the level of CRP (Barnes et al. 2005) suggesting an increased CVD 
risk, but this finding has not been seen in all studies (Campisi and Marengo 2007).  
Tibolone lowers the levels of total cholesterol, LDL cholesterol and lipoprotein(a). In 
addition, it reduces the levels of HDL cholesterol by 20-30% (Mikkola and Clarkson 2002, 
Notelovitz 2007), which has been a cause of concern regarding its cardiovascular safety. The 
decrease in HDL cholesterol may be compensated, at least in part, by the ability of tibolone to 
reduce the levels of triglycerides and thus also the triglyceride/HDL-ratio, which is a predictor of 
CHD risk (Koh et al. 2003, Campisi and Marengo 2007).  
The cardiovascular safety profile of tibolone has been questioned, as conflicting data 
have emerged from clinical trials. In one study the use of tibolone (2.5 mg/day) was associated 
with progression of carotid artery intima-media thickness (CIMT) (Bots et al. 2006). However, this 
effect appeared only in European, but not in American women, a phenomenon the cause of which 
remained unexplained (Clarkson 2006). In contrast, CIMT has also been shown to reduce (Erenus 
et al. 2003), or remain unaltered (Morris et al. 1999, Somunkiran et al. 2006) during tibolone 
therapy. Recently, a smaller dose of tibolone (1.25 mg/day) for 3 years was associated with an 
increased risk of stroke (Cummings et al. 2008). In this trial, however, the mean age of the women 
was as high as 68 years (range 60-85 years). To conclude, with HDL cholesterol excluded, the 
effects of tibolone on the above-mentioned CVD surrogate markers closely resemble those of 








Effects of tibolone on various vascular surrogate markers in postmenopausal women. LDL: low-
density lipoprotein; HDL: high-density lipoprotein; CRP: C-reactive protein; VCAM-1: vascular 
cell adhesion molecule-1; ICAM-1: intercellular adhesion molecule-1; P-selectin: platelet-selectin. 
Effect and reference Marker 
Decrease No effect Increase 
Total cholesterol 
 
Prelevic et al. 2002, Koh et 
al. 2003, Christodoulakos et 
al. 2006 
Cagnacci et al. 1997  
LDL cholesterol 
 
Campisi and Marengo 2007, 






Prelevic et al. 2002, Koh et 
al. 2003, Christodoulakos et 
al. 2006 
Cagnacci et al. 1997  
Triglycerides 
 
Cagnacci et al. 1997, 
Prelevic et al. 2002, Koh et 
al. 2003, Christodoulakos et 
al. 2006 
  
CRP   Koh et al. 2003, 
Vitale et al. 2005, 
Campisi and 
Marengo 2007 
Prelevic et al. 2002, 
Barnes et al. 2005, 
Eilertsen et al. 2008 
VCAM-1 Simoncini and Genazzani 
2000, Egarter et al. 2003, 
Cicinelli et al. 2006 
Vitale et al. 2005  
ICAM-1 Egarter et al. 2003, Cicinelli 
et al. 2006 
Simoncini and 
Genazzani 2000, 











The three main classes of phytoestrogens are isoflavones, lignans and coumestans, among which 
isoflavones are the most important due to their wide range of biological activities (Murkies et al. 
1998, Valachovikova et al. 2004, Finné Nielsen and Williamson 2007). Isoflavones are abundant 
in soybeans, but they are also found in various fruits, vegetables and other plants. The primary 
isoflavones are genistein and daidzein (Murkies et al. 1998, Valachovikova et al. 2004). 
Isoflavones undergo metabolism in the intestine and the liver, where they are subject to 
enterohepatic circulation and excretion into the bile. Isoflavones in soy protein are bound to sugars 
called glucosides. Deglycosylation by β-glucosidase to the biologically active aglycones takes 
place in the gut microflora, where they are quickly absorbed; genistein and daidzein aglycones 
attain maximum serum concentrations at 5-6 hours after ingestion (Setchell et al. 2003b, Finné 
Nielsen and Williamson 2007). The free aglycones are transported to the liver, where they are 
hydroxylated and reconjugated to more water-soluble metabolites and eventually excreted in the 
urine (Murkies et al. 1998, Yuan et al. 2007).  
The consumption of isoflavones is substantially higher in Asia (20-80 mg/day) than 
in Europe and the USA (0.5-3 mg/day) (Tham et al. 1998, Keinan-Boker et al. 2002). The low 
incidence of CVD and cancers of the breast, endometrium and prostate in Asian countries has 
raised the question of whether or not isoflavones have a protective role against these diseases 
(Tikkanen and Adlercreutz 2000, Valachovikova et al. 2004, Sacks et al. 2006).  
Data on the efficacy of isoflavones in the treatment of hot flushes and vaginal dryness 
are not uniform (Adlercreutz and Mazur 1997, Albertazzi and Purdie 2002); hot flushes have been 
found to be reduced in some (Messina and Hughes 2003, Nahas et al. 2007), but not all studies 
(Dalais et al. 1998, Nikander et al. 2003a). Overall, it seems that the effect of isoflavones on 
climacteric symptoms is absent or minimal (Royal College of Obstetricians and Gynaecologists 
2006, Albertazzi 2007, Lethaby et al. 2007, Reed et al. 2008). Additionally, isoflavones appear to 
be ineffective in the prevention of osteoporosis (Sacks et al. 2006, Brink et al. 2008).  
 
Mechanism of action 
 
Isoflavones are structurally similar to 17β-estradiol (Figure 4) and thus they bind to ERs with 
higher affinity to ERβ than to ERα (Valachovicova et al. 2004). Isoflavones can behave as both 
estrogen agonists and antagonists (Tempfer et al. 2007) and thus they are sometimes called natural 
Selective Estrogen Receptor Modulators (SERMs) (Mikkola and Clarkson 2002, Yuan et al. 2007). 
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In addition, isoflavones bind to progesterone and androgen receptors (Beck et al. 2003). 
Isoflavones have also been shown to downregulate androgen receptors (Lund et al. 2004a, 
Hamilton-Reeves et al. 2007). If this is the case in vivo, it could potentially reduce the risk of 
prostate cancer. However, the efficacy and safety of isoflavones in the prevention of breast, 
endometrial and prostate cancer are not established, and adverse effects may also be possible 































Chemical structure of genistein and daidzein, and that of 17β-estradiol for comparison. 
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 Equol  
 
Equol, 7-hydroxy-3-(4’-hydroxyphenyl)-chroman, was first discovered in the urine of a pregnant 
mare and thus the equine-based nomenclature was created (Setchell et al. 2002). Equol has been 
characterized as a nonsteroidal estrogen (Figure 5) which binds to ERα and ERβ (Setchell et al. 
2002). Equol has two isomers: the S-isomer, which is found only in humans, binds to ERβ with a 
similar affinity as 17β-estradiol; the R-isomer, which is not found in humans, shows less affinity to 















Chemical structure of equol, and that of 17β-estradiol for comparison. 
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Equol is produced by the intestinal bacterial flora from daidzein in approximately 30% of humans. 
This is thought to be a stable characteristic that is best revealed after a soy challenge (Setchell et 
al. 2002, Atkinson et al. 2004, Frankenfeld et al. 2004b, Frankenfeld et al. 2005). The definition of 
an equol producer and non-producer varies in the literature. Often a cut-off-point for non-
producers has been a plasma equol level <40 nmol/l (10 µg/l), and for equol producers >83 nmol/l 
(20 µg/l) or a urinary equol level >1000 nmol/l (250 µg/l) (Setchell et al. 2002). The main 
intestinal bacteria responsible for equol production are not known, but at least Bifidobacterium, 
Escherichia coli, Ruminococcus productus, Streptococcus intermedius, Bacteroides ovatus 
(Setchell et al. 2002, Atkinson et al. 2005) and the recently discovered novel bacterium 
Adlercreutzia equolifaciens (Maruo et al. 2008), are involved. Equol production capacity may be 
transitorily affected by the use of antibiotics or by dietary factors; consumption of fat results in 
low equol production, whereas non-starch polysaccharides stimulate bacterial fermentation and 
increase equol formation (Rowland et al. 2000, Setchell et al. 2002). Induction of equol production 
could occur also with probiotics. The most commonly used probiotics are Lactobacilli and 
Bifidobacteria (Fooks and Gibson 2002).  
Equol has a half-life of 8.8 hours (Setchell et al. 2002). In the circulation, 50% of 
equol circulates non-bound, whereas 18.7% of daidzein appears to be free (Setchell et al. 2002). 
Equol binds to SHBG and competitively inhibits the binding of 17β-estradiol and testosterone to 
SHBG in a dose-dependent manner (Martin et al. 1996). Thus, equol increases the availability of 
biologically active fractions of 17β-estradiol and testosterone. On the other hand, equol production 
has been associated with reduced concentrations of estrogens, androgens and cortisol but elevated 
 34 
concentrations of SHBG and progesterone in women of fertile age (Duncan et al. 2000). Equol 
production capacity has been related to a lowered risk of breast and prostate cancer, although the 
data are not uniform (Yuan et al. 2007). Nevertheless, it seems that equol production capacity may 
alter steroid production or metabolism, perhaps through specific colonic bacteria (Duncan et al. 
2000, Frankenfeld et al. 2004a). There are several biological effects in association with 
equol/equol production capacity (Table 4), but the definitive role of this isoflavone metabolite in 






























Biological effects of equol production capacity.  
Effect Reference 
Inhibition of lipid peroxidation  
 
Setchell et al. 2002 
Release of nitric oxide from the endothelium  Hwang et al. 2003, Joy et al. 
2006 
Altered steroid metabolism Duncan et al. 2000, 
Frankenfeld et al. 2004a 
Antioxidant activity: scavenging of free radicals 
 
Setchell et al. 2002 
Lowered risk of breast cancer? 
 
Duncan et al. 2000, Atkinson 
et al. 2005 
Lowered risk of prostate cancer? 
 
Lund et al. 2004b, Atkinson et 
al. 2005, Yuan et al. 2007 
 
 
Effects on cardiovascular risk factors 
 
The assumed vascular benefits of soy were previously thought to be mainly based on its ability to 
lower the concentrations of total cholesterol, LDL cholesterol and triglycerides, and modestly to 
increase the levels of HDL cholesterol (Anderson et al. 1995). The mechanisms behind this action 
are not fully understood, but they may include alterations in cholesterol metabolism and LDL-
receptor activity (Anderson et al. 1995, Clarkson 2002, Wagner et al. 2003). In 1999, the 
American Heart Association stated that 25 g of soy protein daily is protective against CHD 
(Erdman Jr 2000). This recommendation was, however, reversed in 2006 and the cardiovascular 
benefit of soy was regarded as being unlikely (Sacks et al. 2006). Overall, the effect of soy alone 
on lipids and perhaps also on CVDs is nowadays considered minimal (Clarkson 2002, Kreijkamp-
Kaspers et al. 2004, Hall et al. 2005, van der Schouw et al. 2005, Sacks et al. 2006).  
Blood pressure has been shown to decrease during soy supplementation in some 
(Rivas et al. 2002, Welty et al. 2007), but not all studies (Jenkins et al. 2002). Similarly, 
endothelial function (Colacurci et al. 2005) and arterial compliance (Nestel et al. 1997) has either 
improved or remained unaltered (Hale et al. 2002) during treatment with soy or isolated 
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isoflavones. Soy or isolated isoflavones have decreased (Hall et al. 2005) or caused no changes in 
CRP levels (Nikander et al. 2003b, Hanson et al. 2006, Matthan et al. 2007). Furthermore, soy or 
isolated isoflavones have not affected the levels of VCAM-1, ICAM-1 or E-selectin (Blum et al. 
2003, Hall et al. 2005, Greany et al. 2007) (Table 5). The discrepancies between the data 
accumulated from different studies may be explained by differences in type, dose and duration of 
soy supplementation (Clarkson 2002, Dewell et al. 2006). In addition, the presence of both soy 
protein and isoflavones appears to be essential for biological effect (Greaves et al. 1999, Clarkson 
2002). This is important, because different investigators may have used different preparations, 
including intact soy protein, soy protein with isoflavones extracted, or isolated isoflavones 
(Anderson et al. 1995, Erdman Jr 2000, Dewell et al. 2006). Research evidence appears to support 
a role for soy protein in improving lipid status (Sacks et al. 2006).  
In postmenopausal monkeys soy supplementation increases the levels of HDL 
cholesterol (Clarkson et al. 2001a) and decreases the levels of LDL+VLDL cholesterol (Greaves 
et al. 1999, Clarkson et al. 2001a) and this results in inhibited progression of atherosclerosis 
(Honoré et al. 1997, Clarkson et al. 2001a, Wagner et al. 2003). Reduction in the levels of 
VCAM-1 has been observed in atherosclerotic monkeys on a soy diet (Register et al. 2005). It 
should be noted that female monkeys are all equol producers and this may explain different effects 



















Effects of soy or isolated isoflavones on various vascular surrogate markers in postmenopausal 
women. LDL: low-density lipoprotein; HDL: high-density lipoprotein; CRP: C-reactive protein; 
VCAM-1: vascular cell adhesion molecule-1; ICAM-1: intercellular adhesion molecule-1; P-
selectin: platelet-selectin. 
Effect and reference Marker 
Decrease No effect Increase 
Total cholesterol Allen et al. 2007, 
Taku et al. 2007 
Nikander et al. 2004 




Allen et al. 2007, 
Taku et al. 2007 
Nikander et al. 2004, 




 Nikander et al. 2004, 
Colacurci et al. 2005, 
Taku et al. 2007 





Lichtenstein et al. 
2002, Meinertz et al. 
2002 
Colacurci et al. 2005, 
Matthan et al. 2007, 
Taku et al. 2007 
 
CRP Hall et al. 2005 Nikander et al. 2003b, 
Hanson et al. 2006, 
Matthan et al. 2007 
 
VCAM-1 Colacurci et al. 2005, 
Register et al. 2005 
Blum et al. 2003, Hall 
et al. 2005, Greany et 
al. 2007 
 
ICAM-1 Colacurci et al. 2005 Blum et al. 2003, Hall 





 Blum et al. 2003, 








AIMS OF THE STUDY 
 
 
The purpose of the present study was to investigate the effects of soy supplementation on 
predominant markers of cardiovascular risk in non-human primates and postmenopausal women 
using tibolone. Additionally, the impact of equol producing capacity was studied. The specific 
targets were 
 
– the circulating levels of lipids  
 
– blood pressure, arterial stiffness and endothelial function  
 
– the circulating levels of estrone, 17β-estradiol, testosterone, androstenedione, 
DHEAS and SHBG 
 




















SUBJECTS, MATERIALS AND METHODS 
 
 




All primate studies were carried out on 18 cynomolgus monkeys (Macaca fascicularis). These 
animals had been made postmenopausal by means of bilateral oophorectomy 4-6 years prior to the 
study. The monkeys were 19±0.7 (SEM) years of age (range 13-25 years), corresponding to 
middle-aged women.  
The monkeys were studied in compliance with state and federal laws, standards of the 
US Department of Health and Human Services, and guidelines established by the Wake Forest 
University Animal Care and Use Committee. 
The monkeys were assigned to receive one of the four dietary regimens in a random 
order in such a way that all animals received all four diets. The diets contained either 
casein/lactalbumin (C/L) (placebo), tibolone, soy, or soy with tibolone (Figure 6). All diets were 
prepared in the diet laboratory of the Comparative Medicine Research Center (Wake Forest 
University School of Medicine, Winston-Salem, NC, USA) and were formulated to be equivalent 
in cholesterol and macronutrient content (protein, fat, carbohydrate). An essential amino acid, DL-
methionine, was added to the soy-containing diets to make the content of sulfur-containing amino 
acids comparable to that in C/L diets. Detailed composition of the diets is presented in Table 1 of 
Study I. 
  The soy diet provided a woman’s equivalent dose of 138 mg of isoflavones 
(phytoestrogens – genistein, daidzein, glycitein) per day. The soy protein (SUPRO 670-HG, Solae) 
contained, on average, 1.03 mg of genistein, 0.72 mg of daidzein and 0.13 mg of glycitein per 
gram of soy protein isolate (expressed in aglycone units). The tibolone dose was equivalent to a 
woman’s daily dose of 1.25 mg. This dose was adjusted for metabolic differences between 
monkeys and equated to approximately 0.4 mg/monkey/day. Each treatment phase lasted for 14 
weeks. All the monkeys were fed a washout diet (C/L) for 4 weeks before starting the next 
treatment regimen. Blood samples for determination of plasma lipid concentrations were obtained 






















A total of 110 women were studied with the approval of the Ethics Committee of the Department 
of Obstetrics and Gynecology, University of Helsinki, Finland. The study was conducted during 
the years 2003-2007 and all of the women were recruited and studied in Helsinki. All the study 
subjects received written information on the trial and signed a consent document before 
participation. The investigation conforms with the principles outlined in the declaration of 
Helsinki.  
The volunteers were healthy non-smoking postmenopausal women who had used 
tibolone (Livial® 2.5 mg) for >3 months. They consumed a typical Western diet, and findings in 
general and pelvic examination were normal. Further inclusion criteria were body mass index 
(BMI) <33 kg/m2, no use of antihypertensive medication and no use of antibiotics within 3 months 
prior to or during the study. 
  The women were screened for equol production capacity by means of a challenge 
test; soy powder (52 g of soy protein containing 112 mg of isoflavones; 63 mg of genistein, 43 mg 
of daidzein and 6 mg of glycitein expressed as aglycones) (Solae Co. St. Louis, Missouri) mixed 
with food or beverages once a day for one week (Setchell et al. 1984, Setchell et al. 2003a). In our 
study, a 4-fold rise from baseline serum equol concentration was the criterion for equol production 
capability. Twenty women of the 110 screened (18%) fulfilled this criterion. Twenty subsequent 
women without a rise in equol concentrations were studied as non-producers (controls). There was 
a minimum of 4 weeks between the soy challenge and initiation of the actual trial.  
  In the final trial, the two groups of women, 20 equol producers and 20 non-producers, 
were treated in a randomized order for 8 weeks either with a soy powder (52 g of soy protein 
containing 112 mg of isoflavones expressed as aglycones) or with a similar-looking placebo 
powder (containing 52 g of milk protein) (Solae Co. St. Louis, Missouri). The regimens could be 
mixed with food or beverages and taken as a single dose or divided into two daily doses. The first 
treatment period was followed by a washout period of 4 weeks, and then the treatments were 
crossed over for another 8 weeks (Figure 7). The women were encouraged to lead normal lives 
without changes in normal dietary habits, but they were strictly to avoid consuming additional soy-
containing food or supplements. The women were seen at the research center before and at the end 
of each treatment period and blood samples were collected after an overnight fast. Compliance was 











Reprinted (and slightly modified) from: Törmälä R, Appt S, Clarkson TB, Tikkanen MJ, Ylikorkala O, Mikkola TS. 
Individual differences in equol production capability modulate blood pressure in tibolone treated postmenopausal 
women; lack of effect of soy supplementation. Climacteric 2007; 10: 471-479. Copyright (2008) with permission from 









To obtain serum, blood was allowed to clot and serum was separated by centrifugation. Aliquots 
of serum were stored at -80 ºC until analyzed.  
  To obtain plasma, blood was drawn to heparin-containing tubes. Plasma was prepared 





Isoflavones – Monkeys 
 
Serum concentrations of soy isoflavones (genistein, daidzein, equol) were determined by liquid 
chromatographic-photodiode array-electrospray ionization-mass spectrometric analysis at the 
Cancer Research Center of Hawaii, using techniques described previously (Franke et al. 2002). 
The reagents were obtained from Dr. Adrian Franke, Hawaii, USA. Measurements were carried 
out on serum samples collected 4 hours after feeding. Intra-assay coefficients of variation were 
<14% and interassay coefficients of variation ranged between 3-22% (8-22% at levels below 20 
nmol/l, 7-14% at levels of 20-100 nmol/l and 3-12% at levels over 100 nmol/l) for genistein, 
daidzein and equol. The detection limits were 10 nmol/l for genistein and daidzein and 15 nmol/l 
for equol. 
 
Isoflavones – Women 
 
Equol and genistein concentrations were assessed by time-resolved fluoroimmunoassays using 
europium chelate as label and coupling the isoflavone compounds to bovine serum albumin (Table 
6). The final classification for equol producers and non-producers was based on data in the 2 









Characteristics of the assays used for the measurement of genistein and equol in the women on 
long-term tibolone use. TR-FIA: time-resolved fluoroimmunoassay. 
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Lipids – Monkeys 
 
Blood samples for determination of plasma lipid concentrations were obtained twice during each 
treatment phase and collected after food had been withheld for 18 hours. Plasma total cholesterol 
and HDL cholesterol concentrations were measured in the laboratory of the Wake Forest 
University Primate Center using enzymatic methods, and a COBAS FARA II analyzer (Roche 
Diagnostics, Inc., Montclair, New Jersey). The protocols and reagents were supplied by 
Boehringer Mannheim. Plasma HDL cholesterol concentrations were determined using the 
heparin-manganese precipitation procedure (Burstein and Samaille 1960, Manual of Laboratory 
Operations, Lipid Research Clinics Program 1974) (Table 7). Plasma LDL cholesterol plus VLDL 













Characteristics of the assays used for the measurement of total cholesterol and high-density 
lipoprotein (HDL) cholesterol in the monkeys. 








Total cholesterol Boehringer 
Mannheim 
Enzymatic 
methods on the 
COBAS FARA 
II analyzer 
<5% <5% * 






 <5% <5% * 
* no detection limits; detection possible to extend as far as possible by diluting samples 
 
 
Lipids – Women 
 
Concentrations of plasma total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides 
were measured by means of standard methods: plasma total cholesterol and triglycerides 
concentrations were assessed by enzymatic colorimetric methods. Plasma lipoproteins were 
isolated by sequential ultracentrifugation (Havel et al. 1955) using a Beckman optima LE-80K 
ultracentrifuge and a Ti 50.4 rotor; LDL cholesterol was isolated at density range 1.019-1.063 g/ml 
and HDL at density range 1.063-1.21 g/ml. Ultracentrifugally isolated LDL and HDL were further 
purified by gel filtration on Sephadex G25 with phosphate-buffered saline (pH 7.4) as eluting 
solvent. The reagents were supplied by ABX Diagnostics Cholesterol for total cholesterol, LDL 
cholesterol and HDL cholesterol, and by ABX Diagnostics Triglycerides for triglycerides. Intra-
assay coefficients of variation ranged between 0.42-1.26% for total cholesterol, LDL cholesterol 
and HDL cholesterol, and 1.46-1.91% for triglycerides. Interassay coefficients of variation ranged 
between 1.48-2.25% for total cholesterol, LDL cholesterol and HDL cholesterol, and 1.85-3.68% 
for triglycerides. The detection limits were 0.04 mmol/l for total cholesterol, LDL cholesterol and 
HDL cholesterol, and 0.08 mmol/l for triglycerides. 
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Sex steroids and sex hormone-binding globulin 
 
Serum samples from the women were assayed by radioimmunoassay for total estrone (DSL 
Beckmann Coulter, Sinsheim, Germany), by chemiluminescence immunoassay for total 17β-
estradiol, total testosterone (Ortho Clinical Diagnostics, Neckergemünd, Germany), 
androstenedione and DHEAS (DPC Biermann Siemens Medical Solutions, Bad Nauheim, 
Germany). Serum samples were assayed by chemiluminescence immunoenzymetric assay for 
SHBG (DPC Biermann Siemens Medical Solutions, Bad Nauheim, Germany) (Table 8). 
  The free estradiol index was calculated as the ratio: 17β-estradiol (nmol/l) x 100 / 



























Characteristics of the assays used for the measurement of estrone, 17β-estradiol, total testosterone, 
androstenedione, dehydroepiandrosterone sulfate (DHEAS) and sex hormone-binding globulin 
(SHBG) in the women on long-term tibolone use. 














9.0%     14.0% 3.7 
pmol/l 







7.8%     11.8% 9.9 
pmol/l 







5.9%      7.9% 0.17  
nmol/l 








6.7%      11.3% 1.1 
nmol/l 








8.0%      9.8% 0.1  
umol/l 













 Vascular inflammation markers 
 
Levels of CRP in the women were assayed by chemiluminiscence immunoenzymetric assay (DPC 
Biermann Siemens Medical Solutions, Bad Nauheim, Germany). Levels of VCAM-1, ICAM-1 












Characteristics of the assays used for the measurement of C-reactive protein (CRP), vascular cell 
adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and platelet-selectin 
(P-selectin) in the women on long-term tibolone use. 
Analyte Source of reagents Principle of assay Coefficient variation 
Intra-assay  Interassay 
Detection 
limit 







4.7%      9.7% 0.1  
mg/l 
VCAM-1 R&D Systems Enzymeimmuno-
assay  
5.4%      7.9% 0.8  
ng/ml 
ICAM-1 R&D Systems Enzymeimmuno-
assay 
7.3%      9.3% 0.3  
ng/ml 
P-selectin R&D Systems Enzymeimmuno-
assay 





Estrogenic metabolites of tibolone 
 
At the end of the one-week soy challenge, additional serum samples from 20 women (equol 
producers n=11, non-producers n=9) were taken 1-2 hours after tibolone administration to measure 
the estrogenic metabolites of tibolone; 3α-OH-tibolone (Org 4094) and 3β-OH-tibolone (Org 
30126) (NV Organon, Oss, the Netherlands), as described before (Verheul et al. 2007). The 
analytes and internal standards were extracted from plasma by solid phase extraction using 100 
mg, 3 ml Isolute C18 (EC) columns (Sopachem, Wageningen, the Netherlands) and eluted with 
acetonitrile. The analytes were quantified by derivatization under alkaline conditions at room 
temperature using validated gas-chromatography mass-spectrometry (Agilent 6890/5973 GC-
MSD) operated in the positive mode. Coefficients of intra-assay and interassay variation were 
<20% and the detection limits were 0.1 ng/ml for both metabolites. 
 
 
Blood pressure  
 
Blood pressure of the women was measured before and after each study period between 3-7 pm. 
After a minimum of 10 minutes rest in a supine position in a quiet room, blood pressure was 
assessed from the right arm using a validated oscillometric technique (Omron M4-I Intellisense, 
Omron Corporation, Japan) with medium cuff-size. Duplicate measures were taken in each case 
and the mean of the two recordings was used for data analysis. Mean arterial pressure was 
calculated by means of the equation ([2 x diastolic blood pressure] + systolic blood pressure) / 3  
(Franklin et al. 1997).  
 
 
Pulse-wave analysis  
 
Arterial stiffness of the women was assessed by means of pulse-wave analysis (PWA), a validated 
and repeatable method (Wilkinson et al. 2002), using SphygmoCor® equipment (AtCor Medical, 








As the pulse-wave was registered, a generalized transfer function was used to generate a waveform 
to correspond the ascending aortic waveform (central waveform). The aortic augmentation index 
(AIx) was calculated as the augmentation of aortic systolic blood pressure by the reflected pulse-
wave, expressed as a percentage of the aortic pulse pressure. Since AIx is influenced by heart rate, 
AIx adjusted to a heart rate of 75 beats/min, as calculated by the software, was used in the analyses 
(Wilkinson et al. 2002). 
 
Endothelial Function Index 
 
Endothelial function was assessed by using a nitroglycerin and salbutamol challenge. 
Nitroglycerin causes maximal vasodilation independently of the endothelium, whereas salbutamol 
triggers the release of NO from the endothelium and causes maximal endothelium-dependent 
vasodilation. After the baseline PWA recordings, 0.5 mg of nitroglycerin (Nitro resoriblet, Orion 
Pharma, Espoo, Finland) was administered sublingually and AIx was measured 3, 5, 10, 15 and 20 
minutes later. After an hour had passed from the nitroglycerin intake, 2x200 µg salbutamol 
(Ventoline Evohaler, GlaxoSmithKline, Ware, UK) was inhaled using a Volumatic-spacer device) 
and AIx was measured at 5, 10, 15 and 20 minutes. All the PWA measures were carried out in 
triplicate and the mean of the triplicate baseline measurements, and the lowest AIx value after 
nitroglycerin- or salbutamol-induced vasodilation were included in the analyses. An endothelial 
function index (EFI), which expresses endothelium-dependent vasodilation as a percentage of 
endothelium-independent vasodilation, was calculated (Lind et al. 1999, Sarabi et al. 2001, 





The monkey data were analyzed using Statistical Analysis Software (Version 9.1; SAS Institute, 
Inc., Cary, NC). All variables were first evaluated for their distribution and equality of variances 
between groups using univariate analysis and Levene’s test for homogeneity of variance. A mixed 
general linear model with repeated measures was used to determine means and to test for main 
effects of treatment. All variables were screened in the initial model for phase-by-treatment 
 51 
interactions and none were found. All results are expressed as mean±SEM (standard error of 
mean) and a p-value <0.05 was considered statistically significant. 
The human data were analyzed using NCSS software (version 2001, Kaysville, Utah). 
Differences between baseline values and those during treatment were analyzed by the paired t-test. 
Comparison of two treatments (soy versus placebo) and comparison between equol producers and 
non-producers was carried out by the two-sample t-test. Since we used a crossover design, the 
possibility of a period effect was tested by means of the paired t-test, where we compared the 
differences between the periods in the two groups of subjects (those beginning with soy and those 
beginning with placebo); no carryover effect was detected. Thus, the women using soy or placebo 
were analyzed as single groups regardless of the treatment order. The Mann-Whitney U-test, the 
Wilcoxon Rank Sum Test or the Kolmogorov-Smirnov test was used in case of non-normal data 
distribution. Associations between different variables were evaluated by using linear regression 
analysis. All results are expressed as mean±SEM (standard error of mean) and a p-value <0.05 was 
































Total isoflavone concentrations in monkeys fed either the Soy or Soy+Tibolone diet were within 
the range previously reported in other studies (Clarkson et al. 2001a) and were not significantly 
different from each other (p=0.99). The proportion of isoflavone metabolites, equol, daidzein and 
genistein, did not differ between the two diet groups (p>0.15 for all metabolites). Isoflavone levels 





An approximately 14% increase in plasma LDL+VLDL cholesterol was observed in tibolone-
treated monkeys compared with those fed with the control diet (Tibolone vs. C/L p=0.004). Soy 
treatment resulted in an approximately 18% reduction in plasma LDL+VLDL cholesterol (Soy vs. 
C/L p=0.0002) and concomitant supplementation with tibolone did not negate the LDL+VLDL 
cholesterol-lowering effect of soy (Soy+Tibolone vs. Soy p=0.35) (Table 10).  
A 30% increase in HDL cholesterol (Soy vs. C/L p<0.0001) was observed in monkeys 
fed with soy. Monkeys treated with tibolone showed large reductions in plasma HDL cholesterol 
(~48%, Tibolone vs. C/L p<0.0001). Soy+Tibolone diet resulted in conservation of plasma HDL 
cholesterol concentrations, in such a way that monkeys fed with this diet did not differ from 
controls (Soy+Tibolone vs. C/L p=0.09) (Table 10). 
Monkeys treated with tibolone alone showed an increase in the total cholesterol 
(TC):HDL cholesterol ratio of 118% compared with controls (Tibolone vs. C/L p<0.0001). Those 
treated with Soy or Soy+Tibolone showed decreases in the ratio of TC:HDL cholesterol of 34% 




Plasma lipid concentrations (mmol/l) of low-density lipoprotein + very low-density lipoprotein 
cholesterol (LDL+VLDL cholesterol), high-density lipoprotein (HDL) cholesterol, and the ratio of 
total cholesterol (TC) to HDL cholesterol (TC:HDL-ratio) in the monkeys fed either with Soy, 
Tibolone, Soy+Tibolone, or Casein/Lactalbumin (C/L), measured at the end of each diet. Values 
of p denote the differences between the diets. Data are presented as mean±SEM. 
Diet Analyte 
Soy Tibolone Soy+Tibolone C/L 
LDL+VLDL 5.55±0.55 * º 7.67±0.55 ** 5.26±0.55 ** º 6.76±0.55 * 
HDL 1.57±0.1 *** 0.63±0.1 † 1.09±0.1 º 1.21±0.1 *** † º 
TC:HDL-ratio 5.38±1.5 †† ºº 18±1.5 *** 8.0±1.5 º ºº 8.2±1.5 *** †† º 
* p=0.0002  ** p=0.004  *** p<0.0001   
† p<0.0001  †† p=0.03   






Of the 40 women, 33 (82.5%; equol producers n=14, non-producers n=19) completed the study. 
Seven women discontinued the trial; six for personal reasons and one because of a desire to quit 
using tibolone. Three of these (equol producers n=2 and non-producers n=1) completed the 2-
month soy treatment period adequately before dropping out of the trial.  
At baseline, no differences in age, weight, BMI, parity, time since onset of 
menopause or in duration of tibolone use between the equol producers and non-producers were 
found (Table 11). Concentrations of the estrogenic 3α-OH- and 3β-OH-metabolites of tibolone 









Clinical characteristics of the women on long-term tibolone use at baseline. Values are expressed 




n = 40 
Equol producers 
n = 20 
Non-producers 
n = 20 
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Reprinted (and slightly modified) from: Törmälä R, Appt S, Clarkson TB, Mueck AO, Seeger H, Mikkola TS, 
Ylikorkala O. Impact of soy supplementation on sex steroids and vascular inflammation markers in postmenopausal 
women using tibolone: role of equol production capability. Climacteric 2008; 11: 409-415. Copyright (2008) with 





The use of soy was confirmed by 40-fold rises in genistein concentrations (from 28±9.8 up to 
1120±170 nmol/l, p<0.0001) in the entire study group. In the equol producers the genistein rise 
was 92-fold (from 12.6±3.8 up to 1160±282 nmol/l, p=0.0004) and 27-fold in the non-producers 







Changes in levels of genistein after soy and placebo treatment in the women on long-term tibolone 
use; data for equol producers (n=16) and non-producers (n=20) are presented separately. The p-





The concentrations of equol rose 22-fold in the equol producers (from 6.6±1.2 to 144±33.9 nmol/l, 
p=0.0004) and 1.9-fold in the non-producers (from 12.7±1.0 to 24.4±2.8 nmol/l). No changes were 













Changes in levels of equol after soy and placebo treatment in the women on long-term tibolone 
use; data for equol producers (n=16) and non-producers (n=20) are presented separately. The p-
value denotes the difference between baseline and soy treatment in the equol producers. Values are 





Soy supplementation for 2 months resulted in a significant decrease (p=0.006 for difference 
between soy and placebo) in LDL cholesterol compared with placebo treatment. A similar trend 
(p=0.06 for difference between soy and placebo) was observed in total cholesterol concentrations, 
but no effect on HDL cholesterol or triglycerides was seen (Table 12). When the equol producers 
and non-producers were evaluated separately, the reduction in LDL cholesterol levels was 
significant only in the equol producers. There were no differences in lipid concentrations between 








Changes in total cholesterol (TC), low-density lipoprotein cholesterol (LDL), high-density 
lipoprotein cholesterol (HDL) and triglycerides (TG) (all mmol/l) from baseline after soy and 
placebo treatment in the women on long-term tibolone use. Values of p denote the difference 
between baseline and after treatment, or soy vs. placebo. Data are presented as mean±SEM for the 
entire study population (A), and equol producers (B) and non-producers of equol (C) separately. 
 
A. All (n=32) 
Analyte Baseline Soy p Placebo p Soy vs. 
Placebo 
TC 5.25±0.1 4.89±0.2 0.001 5.1±0.1 0.09 p=0.06 
LDL 3.75±0.1 3.37±0.2 0.0003 3.61±0.1 0.07 p=0.006 
HDL 1.38±0.1 1.36±0.1 0.7 1.33±0.1 0.3 p=0.3 
TG 0.97±0.1 0.93±0.1 0.4 0.92±0.1 0.3 p=0.8 
 
 B. Equol producers (n=14) 
Analyte Baseline Soy p Placebo p Soy vs. 
Placebo 
TC 5.35±0.2 4.86±0.2 0.0009 5.09±0.3 0.02 p=0.2 
LDL 3.88±0.3 3.39±0.2 0.0002 3.63±0.2 0.05 p=0.04 
HDL 1.33±0.1 1.34±0.1 0.9 1.27±0.1 0.5 p=0.3 
TG 0.95±0.1 0.94±0.1 0.5 1±0.1 0.5 p=0.5 
 
C. Non-producers of equol (n=18) 
Analyte Baseline Soy p Placebo p Soy vs. 
Placebo 
TC 5.18±0.1 4.92±0.3 0.1 5.13±0.2 0.7 p=0.2 
LDL 3.65±0.1 3.35±0.2 0.04 3.59±0.2 0.6 p=0.07 
HDL 1.42±0.1 1.38±0.1 0.5 1.38±0.1 0.5 p=0.9 
TG 0.99±0.1 0.92±0.1 0.4 0.86±0.1 0.09 p=0.3 
 
Reprinted (and slightly modified) from: Appt S, Törmälä R, Mikkola TS, Tikkanen MJ, Ylikorkala O, Franke AA, 
Clarkson TB. Soy-Tibolone combination – effect on lipids in postmenopausal monkeys and women. Maturitas 2008; 
60: 216-222. Copyright (2008) with permission from Elsevier. 
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Neither soy nor placebo supplementation resulted in a change in body weight. No changes in the 
levels of any lipid correlated with individual changes in serum equol or genistein levels, nor with 




The equol producers compared to the non-producers had significantly lower baseline systolic 
(129.9±2.6 vs. 138.5±3.1 mmHg, p=0.02), diastolic (72.2±1.5 vs. 76.6±1.3 mmHg, p=0.01) and 
mean arterial (93.5±1.7 vs. 99.9±1.8 mmHg, p=0.007) blood pressure. Soy supplementation had 
no effect on blood pressure, but the differences between the equol producers and non-producers 
persisted as regards the systolic, diastolic and mean arterial blood pressure during soy intake 

























Difference in blood pressure among long-term tibolone users producing (n=14) and not producing 
(n=19) equol at baseline and after soy supplementation. Values of p denote differences between 
equol producers and non-producers. NS: non-significant difference. Data are presented as 
mean±SEM. 
 
Reprinted from: Törmälä R, Appt S, Clarkson TB, Tikkanen MJ, Ylikorkala O, Mikkola TS. Individual differences in 
equol production capability modulate blood pressure in tibolone treated postmenopausal women; lack of effect of soy 




Arterial stiffness and endothelial function 
 
At baseline AIx was lower (p=0.01) in the equol producers (25.9±1.1%) than in the non-producers 
(29.6±0.9%). Soy or placebo supplementation had no effect on these levels (Figure 11). 
Augmentation index was not associated with age, BMI or individual equol concentrations before 







Differences in arterial stiffness (expressed as augmentation index) between equol producers 
(n=16) and non-producers (n=20), before and during soy and placebo supplementation among 
long-term tibolone users. Two baseline recordings from each woman are included. Values of p 
denote differences between the groups (equol producers vs. non-producers). Values are expressed 
as mean%±SEM. 
 
Reprinted (and slightly modified) from: Törmälä R, Appt S, Clarkson TB, Groop P-H, Rönnback M, Ylikorkala O, 
Mikkola TS. Equol production capability is associated with favorable vascular function in postmenopausal women 
using tibolone; no effect with soy supplementation. Atherosclerosis 2008; 198: 174-178. Copyright (2008) with 




Similarly, EFI was significantly better (p=0.009) in the equol producers (72.3±5.3%) than in the 
non-producers (55.2±3.8%) at baseline. Soy intake had no significant effect on EFI in either group, 
although a similar trend was observed after soy treatment compared with baseline (Figure 12). No 







Differences in endothelial function (expressed as EFI levels) between equol producers (n=16) and 
non-producers (n=20) at baseline and after soy supplementation among long-term tibolone users. 
Two baseline recordings from each woman are included. Values of p denote differences between 
the groups (equol producers vs. non-producers). Values are expressed as mean%±SEM. EFI: 
endothelial function index. 
 
Sex steroids and sex hormone-binding globulin 
 
At baseline, there were no differences in the levels of sex steroids or SHBG between the equol 
producers and non-producers. Moreover, these levels showed no association with the baseline 
levels of equol or genistein. Parity, age, time since menopause and the duration of tibolone use 
were not determinants of the baseline levels of sex steroids, genistein or equol.  
  In the entire study population soy supplementation was accompanied by a 7.1% 
reduction in estrone levels, whereas placebo had no such effect. The reduction was significant only 
in equol producers (12.5%; p=0.04). The level of testosterone decreased by 15.5% (p=0.02) after 
soy, and this reduction was also seen only in equol producers (22.1%; p=0.03) rather than non-
producers of equol (10%; NS). Free estradiol and androgen indexes showed no changes during soy 





Baseline and post-treatment levels of estrone, 17β-estradiol, total testosterone, free estradiol index, 
free androgen index, androstenedione, dehydroepiandrosterone sulfate (DHEAS) and sex 
hormone-binding globulin (SHBG) in the entire study population (n=36) of long-term tibolone 
users. Data are separately presented for equol producers and non-producers if significant 
differences emerged. Differences denoted by asterisks and daggers refer to differences between 
baseline and post-soy measurements. Values are expressed as mean±SEM.   
Analyte Baseline After soy After placebo 
Estrone (pmol/l) 
    Equol producers (n=16) 










17β-estradiol (pmol/l) 64.9±4.8 67.5±4.8 68.4±7.4 
Free estradiol index 0.43±0.1 0.5±0.1 0.6±0.1 
Testosterone (pmol/l) 
    Equol producers (n=16) 










Free androgen index 3.7±0.5 4.0±0.5 4.3±0.6 
Androstenedione (nmol/l) 4.7±0.3 4.4±0.3 4.4±0.3 
DHEAS (umol/l) 3.1±0.3 3.3±0.3 3.1±0.3 
SHBG (nmol/l) 19.3±1.5 †  †† 15.6±1.2 † 15.0±1.2 †† 
* p=0.04       ** p=0.02       *** p=0.03       † p=0.0003       †† p=0.03 
 
Reprinted (and slightly modified) from: Törmälä R, Appt S, Clarkson TB, Mueck AO, Seeger H, Mikkola TS, 
Ylikorkala O. Impact of soy supplementation on sex steroids and vascular inflammation markers in postmenopausal 
women using tibolone: role of equol production capability. Climacteric 2008; 11: 409-415. Copyright (2008) with 
permission from Taylor and Francis. 
   
 
Vascular inflammation markers 
 
At baseline, there were no differences in the levels of CRP or adhesion molecules between the 
equol producers and non-producers. Parity, age, time since menopause or the duration of tibolone 
use were not determinants of the baseline levels of inflammation markers, genistein or equol.  
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  The levels of CRP and ICAM-1 showed no changes after the use of soy, whereas the 
levels of VCAM-1 increased by 9.2% (p=0.06) and those of P-selectin decreased by 10.3% 
(p=0.002). The reduction in P-selectin was larger the longer tibolone had been used (r=-0.63; 
p=0.009). Equol producers showed a larger reduction in P-selectin than non-producers of equol 




Baseline and post-treatment levels of C-reactive protein (CRP), vascular cell adhesion molecule-1 
(VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and platelet-selectin (P-selectin) in the 
entire study population (n=36) of long-term tibolone users. Data are separately presented for equol 
producers and non-producers if significant differences emerged. Differences denoted by asterisks 
refer to differences between baseline and post-soy measurements. Values are expressed as 
mean±SEM.  
Analyte Baseline After soy After placebo 
CRP (mg/l) 2.4±0.4 2.46±0.4 2.3±0.3 
VCAM-1 (ng/ml) 512±17.5 * 559±22.8 * 511±19.8 
ICAM-1 (ng/ml) 211±10.1 210±9.6 198±8.3 
P-selectin (ng/ml) 
    Equol producers (n=16) 










* p=0.06  ** p=0.002  *** p=0.007 
 
Reprinted (and slightly modified) from: Törmälä R, Appt S, Clarkson TB, Mueck AO, Seeger H, Mikkola TS, 
Ylikorkala O. Impact of soy supplementation on sex steroids and vascular inflammation markers in postmenopausal 
women using tibolone: role of equol production capability. Climacteric 2008; 11: 409-415. Copyright (2008) with 
permission from Taylor and Francis. 
 
 
Levels of equol showed no relationship to changes in the levels of steroids or inflammation 
markers, except a significant relationship between concentrations of equol and DHEAS in equol 
producers (r=0.65, p=0.007) at baseline and after soy supplementation (r=0.51, p=0.04). The soy-






Tibolone is an effective alternative for the treatment of menopausal symptoms (Speroff and 
Clarkson 2003, Kenemans and Speroff 2005, Notelovitz 2007) and approximately 15 000 women 
used it in Finland in 2007 (The Social Insurance Institute of Finland). It does not cause withdrawal 
bleeding and may improve sexual well-being (Kloosterboer 2001, Reed and Kloosterboer 2004).  
A major concern as regards the use of tibolone has been the reduction in the levels of 
cardioprotective HDL cholesterol (Notelovitz 2007). Although tibolone decreases the levels of 
triglycerides at the same time, which may counteract the negative effect of falling concentrations 
of HDL cholesterol, the cardiovascular safety of tibolone has been questioned (Bots et al. 2006). 
Indeed, CIMT progression rates have been found to be higher with tibolone compared with 
placebo. Interestingly, separating the women into Europeans and Americans an increase in mean 
CIMT was found in European women after tibolone compared with placebo, whereas no effect 
was seen in American women (Bots et al. 2006, Clarkson 2006). So far there exists no explanation 
for this alarming phenomenon, but perhaps dietary factors could be involved. This brings out the 
use of soy, which shows national differences (Keinan-Boker et al. 2002, Consumer attitudes about 
nutrition 2007). 
The cynomolgus macaque study model has been used for more than three decades 
and is suitable for evaluating the effects of a given regimen on atherosclerosis progression, 
especially in women (Clarkson et al. 2001a-b). First, cynomolgus macaques resemble humans in 
that there is 94% DNA homology (Clarkson et al. 2004). Second, female macaques have a similar 
menstrual cycle and menopause profile as in women. Again, similarly to women, premenopausal 
female macaques have higher circulating HDL cholesterol levels and less coronary artery 
atherosclerosis than male monkeys (Clarkson 2007). In a previous study with monkeys, tibolone 
did not worsen coronary artery atherosclerosis despite a reduction in HDL cholesterol levels 
(Clarkson et al. 2004). In the present study in postmenopausal monkeys, the tibolone-induced 
HDL cholesterol reduction (-48%) was reversed with a soy diet; the ratio of total cholesterol to 
HDL cholesterol was also reduced (Study I). 
  The results from the monkey study led us to explore whether soy supplementation 
would have similar effects on circulating lipids in postmenopausal women using tibolone. 
Additionally, other predominant markers of CVD risk (blood pressure, arterial stiffness, 
endothelial function) were included. Furthermore, of the various circulating surrogate markers of 
CVD (Mueck and Seeger 2006), we chose to study estrogens, testosterone, androstenedione, 
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DHEAS, SHBG and markers of vascular inflammation and adhesion, since changes in these are 
connected to CVD risk, particularly in women (Davison and Davis 2003, Mueck and Seeger 2006, 
Clarkson 2008). In our study, the female volunteers were healthy long-time users of tibolone. 
Based on previous studies, it was judged that both the exposure time and dosage of the soy 
regimen we used in our study should be adequate for triggering any effects of soy if such existed 
(Tham et al. 1998, Dalais et al. 2003, Nikander et al. 2004). Consistent elevations in serum 
genistein levels in our study subjects confirmed that the women had used soy as instructed. We 
used a minimum of a 4-fold elevation from baseline serum equol level as a sign of equol 
producing capacity, and this is a more strict criterion than employed in many previous studies 
(Frankenfeld et al. 2004a-b, Grace et al. 2004, Kreijkamp-Kaspers et al. 2005). Therefore, only 
18% of our study subjects fulfilled this criterion, but we may assume that all these subjects were 
truly equol producers.  
We observed decreases in the levels of total and LDL cholesterol during soy 
supplementation in postmenopausal women using tibolone, but no effect on HDL cholesterol. The 
longer soy supplementation period (14 weeks) in the monkeys compared with the women (8 
weeks) may account for differences in LDL cholesterol reductions and the lack of effect on HDL 
cholesterol. In addition, in monkeys, cholesterol in the blood is mainly derived from freely 
absorbed cholesterol, whereas in women the majority of circulating cholesterol originates from the 
liver. Finally, all monkeys produce equol (Gu et al. 2006), whereas only 18% of women did so in 
our study.  
Soy supplementation showed no effect on blood pressure in tibolone users in our 
study. Previously, soy has been found to decrease (Rivas et al. 2002, Welty et al. 2007) or has not 
affected (Jenkins et al. 2002) blood pressure. However, in these studies the postmenopausal 
women were not using tibolone and therefore direct comparison is difficult, as no previous data 
exist on the concomitant use of tibolone and soy. Interestingly, in our study blood pressure was 
already lower in equol producers before the beginning of soy supplementation, and this feature 
persisted during soy treatment. Equol itself is unlikely to reduce blood pressure, since the baseline 
equol concentrations did not differ between equol producers and non-producers. Our findings are 
not likely to have resulted from equol-related changes in the metabolism of tibolone, because 
levels of the estrogenic metabolites of tibolone showed no difference between equol producers and 
non-producers. More likely, equol production capability may just be a new marker in the 
regulation of blood pressure. Equol may increase renal sodium output (Giménez et al. 1997), 
which in theory should decrease blood pressure. Furthermore, equol has shown vasorelaxant 
activity in the cerebral arteries of normotensive rats, similarly to daidzein, whereas in hypertensive 
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rats this was the case only with equol (Jackman et al. 2007). Of course it is also possible that equol 
may have direct vascular effects (Chin-Dusting et al. 2001), but the exact mechanism and whether 
it is endothelium-dependent or -independent, is unknown.  
Soy supplementation did not affect arterial stiffness or endothelial function in 
tibolone users in our study. Previous data have shown improved endothelial function during soy 
supplementation in postmenopausal women not using tibolone (Cuevas et al. 2003, Steinberg et al. 
2003, Colacurci et al. 2005), although this finding has not been seen in all studies (Hale et al. 
2002, Kreijkamp-Kaspers et al. 2005, Evans et al. 2007). Soy may, however, have different effects 
in tibolone users and non-users, particularly if the women are equol producers. In our study, equol 
producers at baseline had less arterial stiffness and better endothelial function than non-producers 
of equol. The lower augmentation index and higher endothelial function index also persisted after 
soy supplementation. Thus, tibolone users producing equol may have more compliant arteries than 
non-producers, even in the absence of soy intake. This finding may also imply a direct vascular 
effect of equol. 
The levels of estrone and testosterone decreased during soy treatment in tibolone 
users. Similar reductions during the use of soy have been reported earlier in premenopausal 
women (Duncan et al. 2000), and also in monkeys not exposed to tibolone (Wood et al. 2007). Soy 
may have acted via various pathways, perhaps by increasing the activity of 5α-reductase, which 
converts testosterone to 5α-dihydrotestosterone. It also increases the activity of sulfotransferase, 
which results in increased elimination of estrone. The latter is, however, unlikely in view of a 
previous study where soy, and equol in particular, were potent inhibitors of this enzyme (Harris et 
al. 2004) and therefore other explanations seem more likely. According to Atkinson et al., the fecal 
bacteria of equol producers are capable of metabolizing more estrone to 17β-estradiol, and 16α-
hydroxyestrone to estriol (Atkinson et al. 2006). This may also have been the case in our study, as 
changes in the levels of testosterone and estrone were more pronounced in equol producers. No 
significant changes occurred in the free estradiol index, the free androgen index, or levels of 
SHBG, androstenedione, or DHEAS. The significant relationship observed between the circulating 
levels of DHEAS and equol in the equol producers may imply that equol is involved in the 
regulation of androgens of the adrenal cortex in women using tibolone, and in principle a similar 
finding has been reported in men (Lewis et al. 2005).  
  Supplementation with soy or isolated isoflavones has decreased (Hall et al. 2005) or 
brought about no changes in the levels of CRP (Nikander et al. 2003b, Hanson et al. 2006, 
Matthan et al. 2007), and brought about no changes in the levels of VCAM-1, ICAM-1 or E-
selectin (Hall et al. 2005). In our tibolone users, soy supplementation did not affect the levels of 
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CRP or ICAM-1, whereas the levels of VCAM-1 increased; the latter can be taken as a sign of 
potential endothelial dysfunction (Blankenberg et al. 2003). In contrast, at the same time, the 
levels of P-selectin fell, which in theory is a favorable effect (Blankenberg et al. 2003). The 
reduction in P-selectin was more pronounced in the equol producers and hence equol might 
participate in platelet aggregation. Taken together, soy supplementation brought about such small 
changes in the levels of vascular inflammation and adhesion markers in postmenopausal women 
using tibolone that their clinical significance is likely to be modest. 
  
  To conclude, soy supplementation reversed the tibolone-induced fall in HDL 
cholesterol levels in postmenopausal monkeys. However, this effect of soy was not seen in 
postmenopausal women using tibolone. Soy supplementation in tibolone users failed to modify 
blood pressure, arterial stiffness or endothelial function, but equol production capability itself was 
associated with beneficial cardiovascular changes in postmenopausal women using tibolone. Our 
data do not justify recommending assessment of equol production status in postmenopausal 
women in clinical practice in general. More data are needed in women using and not using 























In postmenopausal monkeys, co-administration of soy and tibolone improved the lipid profile by 
maintaining the level of HDL cholesterol (compared with a 48% decrease with tibolone alone), by 
lowering the level of LDL+VLDL cholesterol in a similar manner (22%) as soy treatment alone 
(18%), and by maintaining the ratio of total cholesterol to HDL cholesterol. These effects may 
offer cardiovascular protection. 
 
In postmenopausal women, the administration of soy in long-term tibolone users modestly 
improved the lipid profile by way of reductions in the levels of total cholesterol and LDL 
cholesterol, whereas HDL cholesterol was not affected. 
 
Postmenopausal women using tibolone and producing equol had lower blood pressure, more 
compliant arteries and better endothelial function than non-producers of equol. These findings may 
imply cardiovascular benefits in postmenopausal tibolone users producing equol.  
 
The decreases in the levels of estrone and testosterone brought about by soy supplementation or 
equol production capacity may imply differences in steroid metabolism between equol producers 
and non-producers, but the clinical significance of this finding is unknown.  
 
The effect of soy supplementation or equol production capacity on vascular inflammation and 
adhesion markers in postmenopausal women using tibolone were only minor and the changes are 
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